Indication-specific dosing for (lycopus), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Sections

Sections Lycopus
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Suggested Dosing

0.2-2 g/day whole herb PO

Commerically available preparation: 2 tablet (40 mg) PO qD

Suggested Uses

Hyperthyroidism, PMS, breast pain, nervousness, insomnia; and bleeding, especially nosebleeds and heavy bleeding during menses

Efficacy

There is insufficient reliable information available about the effectiveness

Interaction Checker

Enter a drug name and Lycopus

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Contraindicated (0)

Serious - Use Alternative (2)

levothyroxine
lycopus decreases effects of levothyroxine by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.
thyroid desiccated
lycopus decreases effects of thyroid desiccated by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.

Monitor Closely (3)

iodine (radioactive)
lycopus increases effects of iodine (radioactive) by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.
methimazole
lycopus increases effects of methimazole by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.
propylthiouracil
lycopus increases effects of propylthiouracil by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.

Minor (23)

acarbose
lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
chlorpropamide
lycopus increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glimepiride
lycopus increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glipizide
lycopus increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glyburide
lycopus increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin aspart
lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin detemir
lycopus increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin glargine
lycopus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin glulisine
lycopus increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin lispro
lycopus increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin NPH
lycopus increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin regular human
lycopus increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
metformin
lycopus increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
miglitol
lycopus increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
nateglinide
lycopus increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
pioglitazone
lycopus increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
repaglinide
lycopus increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
rosiglitazone
lycopus increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
saxagliptin
lycopus increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
sitagliptin
lycopus increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
tolazamide
lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
tolbutamide
lycopus increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
vildagliptin
lycopus increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

acarbose
Minor (1)lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
chlorpropamide
Minor (1)lycopus increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glimepiride
Minor (1)lycopus increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glipizide
Minor (1)lycopus increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
glyburide
Minor (1)lycopus increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin aspart
Minor (1)lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin detemir
Minor (1)lycopus increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin glargine
Minor (1)lycopus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin glulisine
Minor (1)lycopus increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin lispro
Minor (1)lycopus increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin NPH
Minor (1)lycopus increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
insulin regular human
Minor (1)lycopus increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
iodine (radioactive)
Monitor Closely (1)lycopus increases effects of iodine (radioactive) by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.
levothyroxine
Serious - Use Alternative (1)lycopus decreases effects of levothyroxine by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.
metformin
Minor (1)lycopus increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
methimazole
Monitor Closely (1)lycopus increases effects of methimazole by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.
miglitol
Minor (1)lycopus increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
nateglinide
Minor (1)lycopus increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
pioglitazone
Minor (1)lycopus increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
propylthiouracil
Monitor Closely (1)lycopus increases effects of propylthiouracil by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.
repaglinide
Minor (1)lycopus increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
rosiglitazone
Minor (1)lycopus increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
saxagliptin
Minor (1)lycopus increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
sitagliptin
Minor (1)lycopus increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
thyroid desiccated
Serious - Use Alternative (1)lycopus decreases effects of thyroid desiccated by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.
tolazamide
Minor (1)lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
tolbutamide
Minor (1)lycopus increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
vildagliptin
Minor (1)lycopus increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

Adverse Effects

None in regular doses

Contraindications

Pregnancy, lactation

Hypothyroidism

Cautions

May cause hypoglycemia

Pregnancy & Lactation

Pregnancy Category: avoid

Lactation: avoid

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Pharmacology

Metabolism: N/A

Excretion: N/A

Mechanism of Action

Contains organic acids, eg, lithospermic acid that decrease levels of several hormones, particularly TSH & thyroxine (T4)

Also inhibits binding of antibodies to thyroid that cause Graves disease

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections Lycopus
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Lycopus (Herb/Suppl)